ALNY insider transaction filings
ALNYLAM PHARMACEUTICALS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-03. Screen ALNY transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-03 | 4 | Cravatt Benjamin — Director | Grant/award (A): 4,393 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | PYOTT DAVID E I — Director | Option exercise (M): 3,830 @ $0 · Sale (S): 921 @ $297.71 · Sale (S): 1,175 @ $298.91 · Sale (S): 1,222 @ $299.87 · Sale (S): 495 @ $300.72 · Sale (S): 17 @ $302.65 · +1 more | EDGAR |
| 2026-05-22 | 4 | Sigal Charles Elliott — Director | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | SCHULMAN AMY W — Director | Grant/award (A): 838 @ $0 · Grant/award (A): 1,802 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Reitan Colleen F — Director | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | KELLOGG PETER N — Director | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | HAMBURG MARGARET A — Director | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | BRANDICOURT OLIVIER — Director | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Ausiello Dennis A — Director | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Arbuckle Stuart A — Director | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | PYOTT DAVID E I — Director | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | SCHULMAN AMY W — Director | Option exercise (M): 11,250 @ $70.20 · Option exercise (M): 11,250 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | McLaughlin Melissa — Chief Human Resources Officer | Sale (S): 265 @ $316.61 · Sale (S): 359 @ $317.44 · Sale (S): 209 @ $318.47 · Sale (S): 86 @ $319.69 · Sale (S): 147 @ $320.62 · Sale (S): 224 @ $321.64 · +8 more | EDGAR |
| 2026-03-06 | 4 | Garg Pushkal — EVP Chief R&D | Sale (S): 106 @ $319.03 · Sale (S): 102 @ $320.01 · Sale (S): 215 @ $320.81 · Sale (S): 289 @ $321.82 · Sale (S): 350 @ $323.01 · Sale (S): 767 @ $323.84 · +6 more | EDGAR |
| 2026-03-06 | 4 | Greenstreet Yvonne — Chief Executive Officer, Director | Sale (S): 135 @ $319.03 · Sale (S): 129 @ $320.01 · Sale (S): 274 @ $320.81 · Sale (S): 368 @ $321.82 · Sale (S): 444 @ $323.01 · Sale (S): 973 @ $323.84 · +2 more | EDGAR |
| 2026-03-06 | 4 | Poulton Jeffrey V. — EVP, Chief Financial Officer | Sale (S): 114 @ $319.03 · Sale (S): 109 @ $320.01 · Sale (S): 230 @ $320.81 · Sale (S): 309 @ $321.82 · Sale (S): 374 @ $323.01 · Sale (S): 818 @ $323.84 · +2 more | EDGAR |
| 2026-03-06 | 4 | Tanguler Tolga — EVP, Chief Commercial Officer | Sale (S): 106 @ $319.03 · Sale (S): 102 @ $320.01 · Sale (S): 215 @ $320.81 · Sale (S): 289 @ $321.82 · Sale (S): 350 @ $323.01 · Sale (S): 767 @ $323.84 · +2 more | EDGAR |
| 2026-03-06 | 4 | Fitzgerald Kevin Joseph — CSO & EVP, Head of Research | Sale (S): 29 @ $319.03 · Sale (S): 28 @ $320.01 · Sale (S): 59 @ $320.81 · Sale (S): 79 @ $321.82 · Sale (S): 96 @ $323.01 · Sale (S): 210 @ $323.84 · +6 more | EDGAR |
| 2026-03-04 | 4 | Poulton Jeffrey V. — EVP, Chief Financial Officer | Grant/award (A): 4,769 @ $0 · Sale (S): 65 @ $323.62 · Sale (S): 124 @ $324.65 · Sale (S): 356 @ $325.63 · Sale (S): 541 @ $326.81 · Sale (S): 454 @ $327.67 · +6 more | EDGAR |
| 2026-03-04 | 4 | Garg Pushkal — EVP Chief R&D | Grant/award (A): 4,769 @ $0 · Sale (S): 50 @ $323.62 · Sale (S): 97 @ $324.65 · Sale (S): 277 @ $325.63 · Sale (S): 421 @ $326.81 · Sale (S): 353 @ $327.67 · +10 more | EDGAR |
| 2026-03-04 | 4 | Fitzgerald Kevin Joseph — CSO & EVP, Head of Research | Grant/award (A): 3,688 @ $0 · Sale (S): 47 @ $323.62 · Sale (S): 90 @ $324.65 · Sale (S): 258 @ $325.63 · Sale (S): 392 @ $326.81 · Sale (S): 329 @ $327.67 · +10 more | EDGAR |
| 2026-03-04 | 4 | Tanguler Tolga — EVP, Chief Commercial Officer | Grant/award (A): 4,769 @ $0 · Sale (S): 47 @ $323.62 · Sale (S): 90 @ $324.65 · Sale (S): 258 @ $325.63 · Sale (S): 392 @ $326.81 · Sale (S): 329 @ $327.67 · +6 more | EDGAR |
| 2026-03-04 | 4 | SUPRAN BRYAN — EVP, CLO and Secretary | Grant/award (A): 1,539 @ $0 · Grant/award (A): 3,381 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Greenstreet Yvonne — Chief Executive Officer, Director | Grant/award (A): 13,844 @ $0 · Sale (S): 200 @ $323.62 · Sale (S): 382 @ $324.65 · Sale (S): 1,098 @ $325.63 · Sale (S): 1,669 @ $326.81 · Sale (S): 1,399 @ $327.67 · +7 more | EDGAR |
| 2026-03-02 | 4 | Greenstreet Yvonne — Chief Executive Officer, Director | Option exercise (M): 5,921 @ $0 · Option exercise (M): 5,921 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Poulton Jeffrey V. — EVP, Chief Financial Officer | Option exercise (M): 1,908 @ $0 · Option exercise (M): 1,908 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Tanguler Tolga — EVP, Chief Commercial Officer | Option exercise (M): 1,666 @ $0 · Option exercise (M): 1,666 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Garg Pushkal — EVP Chief R&D | Option exercise (M): 1,908 @ $0 · Sale (S): 127 @ $328.92 · Sale (S): 2,259 @ $330.73 · Sale (S): 1,159 @ $331.49 · Sale (S): 942 @ $332.48 · Sale (S): 140 @ $334.39 · +1 more | EDGAR |
| 2026-02-25 | 4 | Fitzgerald Kevin Joseph — CSO & EVP, Head of Research | Grant/award (A): 158 @ $0 | EDGAR |
| 2026-02-17 | 4 | Garg Pushkal — EVP Chief R&D | Grant/award (A): 4,579 @ $0 · Sale (S): 2,242 @ $310.08 | EDGAR |
| 2026-02-17 | 4 | Greenstreet Yvonne — Chief Executive Officer, Director | Grant/award (A): 14,209 @ $0 · Sale (S): 6,958 @ $310.08 | EDGAR |
| 2026-02-17 | 4 | Tanguler Tolga — EVP, Chief Commercial Officer | Grant/award (A): 4,000 @ $0 · Sale (S): 1,959 @ $310.08 | EDGAR |
| 2026-02-17 | 4 | Fitzgerald Kevin Joseph — CSO & EVP, Head of Research | Grant/award (A): 4,000 @ $0 · Sale (S): 1,959 @ $310.08 · Sale (S): 2,041 @ $331.96 | EDGAR |
| 2026-02-17 | 4 | Poulton Jeffrey V. — EVP, Chief Financial Officer | Grant/award (A): 4,579 @ $0 · Sale (S): 2,242 @ $310.08 | EDGAR |
| 2026-01-14 | 4 | Garg Pushkal — EVP Chief R&D | Grant/award (A): 3,800 @ $0 · Sale (S): 39 @ $353.95 · Sale (S): 42 @ $355.16 · Sale (S): 41 @ $356.09 · Sale (S): 96 @ $357.17 · Sale (S): 123 @ $358.18 · +16 more | EDGAR |
| 2026-01-14 | 4 | Greenstreet Yvonne — Chief Executive Officer, Director | Grant/award (A): 19,003 @ $0 · Sale (S): 247 @ $353.95 · Sale (S): 269 @ $355.16 · Sale (S): 263 @ $356.09 · Sale (S): 607 @ $357.17 · Sale (S): 778 @ $358.18 · +16 more | EDGAR |
| 2026-01-14 | 4 | Poulton Jeffrey V. — EVP, Chief Financial Officer | Grant/award (A): 6,193 @ $0 · Sale (S): 72 @ $353.95 · Sale (S): 78 @ $355.16 · Sale (S): 76 @ $356.09 · Sale (S): 176 @ $357.17 · Sale (S): 226 @ $358.18 · +16 more | EDGAR |
| 2026-01-14 | 4 | Tanguler Tolga — EVP, Chief Commercial Officer | Grant/award (A): 3,800 @ $0 · Sale (S): 39 @ $353.95 · Sale (S): 42 @ $355.16 · Sale (S): 41 @ $356.09 · Sale (S): 96 @ $357.17 · Sale (S): 123 @ $358.18 · +16 more | EDGAR |
| 2026-01-14 | 4 | Fitzgerald Kevin Joseph — CSO & EVP, Head of Research | Grant/award (A): 3,800 @ $0 · Sale (S): 39 @ $353.95 · Sale (S): 42 @ $355.16 · Sale (S): 41 @ $356.09 · Sale (S): 96 @ $357.17 · Sale (S): 123 @ $358.18 · +22 more | EDGAR |
| 2026-01-07 | 4 | Arbuckle Stuart A — Director | Grant/award (A): 3,279 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | Greenstreet Yvonne — Chief Executive Officer, Director | Option exercise (M): 839 @ $119.13 · Option exercise (M): 2,352 @ $85 · Option exercise (M): 847 @ $118.05 · Option exercise (M): 659 @ $151.59 · Tax withholding (F): 1,121 @ $445.12 · Option exercise (M): 2,352 (derivative) @ $0 · +3 more | EDGAR |
| 2025-11-19 | 4 | Fitzgerald Kevin Joseph — CSO & EVP, Head of Research | Option exercise (M): 8,161 @ $119.13 · Sale (S): 8,168 @ $449 · Sale (S): 96 @ $450.09 · Sale (S): 129 @ $451.51 · Sale (S): 368 @ $455.24 · Sale (S): 364 @ $456.25 · +7 more | EDGAR |
| 2025-11-14 | 4 | Greenstreet Yvonne — Chief Executive Officer, Director | Option exercise (M): 650 @ $42.22 · Option exercise (M): 15,000 @ $119.13 · Sale (S): 711 @ $448.07 · Sale (S): 2,132 @ $449.15 · Sale (S): 453 @ $450.17 · Sale (S): 1,255 @ $451.16 · +20 more | EDGAR |
| 2025-10-03 | 4 | SUPRAN BRYAN — EVP, CLO and Secretary | Grant/award (A): 13,026 @ $0 | EDGAR |
| 2025-10-03 | 4 | Poulton Jeffrey V. — EVP, Chief Financial Officer | Grant/award (A): 3,108 @ $0 · Grant/award (A): 4,644 @ $0 · Sale (S): 150 @ $446.53 · Sale (S): 73 @ $447.92 · Sale (S): 234 @ $448.77 · Sale (S): 324 @ $449.79 · +8 more | EDGAR |
| 2025-10-03 | 4 | Greenstreet Yvonne — Chief Executive Officer, Director | Grant/award (A): 3,860 @ $0 · Grant/award (A): 14,252 @ $0 · Sale (S): 350 @ $446.53 · Sale (S): 171 @ $447.92 · Sale (S): 548 @ $448.77 · Sale (S): 758 @ $449.79 · +8 more | EDGAR |
| 2025-10-03 | 4 | Tanguler Tolga — EVP, Chief Commercial Officer | Grant/award (A): 2,851 @ $0 · Sale (S): 55 @ $446.53 · Sale (S): 27 @ $447.92 · Sale (S): 86 @ $448.77 · Sale (S): 119 @ $449.79 · Sale (S): 260 @ $450.81 · +7 more | EDGAR |
| 2025-10-03 | 4 | Fitzgerald Kevin Joseph — CSO & EVP, Head of Research | Grant/award (A): 2,102 @ $0 · Grant/award (A): 2,851 @ $0 · Sale (S): 96 @ $446.53 · Sale (S): 47 @ $447.92 · Sale (S): 150 @ $448.77 · Sale (S): 207 @ $449.79 · +8 more | EDGAR |
| 2025-10-03 | 4 | Garg Pushkal — EVP Chief R&D | Grant/award (A): 3,108 @ $0 · Grant/award (A): 2,851 @ $0 · Sale (S): 115 @ $446.53 · Sale (S): 56 @ $447.92 · Sale (S): 180 @ $448.77 · Sale (S): 249 @ $449.79 · +13 more | EDGAR |
| 2025-09-11 | 4 | Reitan Colleen F — Director | Option exercise (M): 18,000 @ $100.65 · Sale (S): 1,645 @ $457.44 · Sale (S): 1,888 @ $458.86 · Sale (S): 1,403 @ $459.73 · Sale (S): 473 @ $460.71 · Sale (S): 2,290 @ $461.92 · +12 more | EDGAR |
Recent 8-K events — ALNYLAM PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2025-12-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-10-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ALNY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →